Fujifilm ECR2023

Seno Medical unveils commercial version of Imagio opto-acoustic/ultrasound breast imaging system

Seno Medical has officially launched the commercial version of their Imagio Breast Imaging System – a revolutionary new modality in breast imaging. Recently recognized with a Gold Edison award, a Gold Medical Design Excellence Award, and as a semi-finalist in the Minnies 2022 competition for its medical innovation, Seno’s groundbreaking diagnostic breast cancer imaging system helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information about breast lesions in real time, helping providers to characterize masses that may – or may not – require more invasive diagnostic evaluation.

The market-ready Imagio system received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US FDA in June 2022; it incorporates the latest in ultrasound imaging technology required for premier breast imaging centres, as well as advanced ultrasound technology integrated into the opto-acoustic probe, a new ultrasound probe, and elimination of redundant electronics, making this version of Imagio ergonomic and truly disruptive for the marketplace with its novel technological advances.

Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer – angiogenesis and hypoxia – Seno Medical has shown that the Imagio OA/US breast imaging system will be a more effective tool to help radiologists confirm or rule out malignancy compared with traditional diagnostic imaging modalities. And it does this without exposing patients to potentially harmful ionizing radiation or contrast agents. In addition to the novel imaging provided by the Imagio system, Seno includes an artificial intelligence decision-support tool (SenoGram) to aid physicians in interpreting the new images. This AI tool, along with training and certifi-cation, helps radiologists transition from ultrasound alone  to OA/US imaging.

For more information, visit: www.SenoMedical.com.

Digital issue: Please click here for more information

Fujifilm ECR2023